Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A clinical study on the Efficacy and safety of luspatercept in Chinese patients with non-transfusion-dependent β-thalassemia

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHe LiTNTing NiuXYXinwei Yu

Discussion

Loading...

Member takes

Overview

This clinical study demonstrates the efficacy and safety of luspatercept in improving hemoglobin levels in Chinese patients with β-thalassemia, suggesting it as a viable treatment option.

Key Points

  • Luspatercept effectively increased hemoglobin levels by 2.1 g/dL in patients with β-thalassemia within 24 weeks.
  • Adverse events were similar to those commonly reported, with no severe events noted.
  • This multicenter, open-label study included 50 patients with a mean hemoglobin level of 7.3 g/dL.
  • The findings support luspatercept as a well-tolerated treatment for anemia related to β-thalassemia.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e47dhttps://doi.org/10.1182/blood-2025-1142
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety data from the non-transfusion-dependent dose-confirmation cohort: A phase 2a study of luspatercept in pediatric patients with β-thalassemia2025 · 1 citations
  2. 2Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis2026
  3. 3Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study2025 · 7 citations
  4. 4Luspatercept in β-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations2025
  5. 5Outcomes with luspatercept in patients with β-thalassemia: A systematic review and meta-analysis2025